Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom
Abstract Objective Investigate real‐world outcomes in drug‐resistant epilepsy (DRE) patients treated with cenobamate as adjunctive treatment to other antiseizure medications (ASMs) within the Early Access Programs (EAP) in Germany, France, and the United Kingdom. Methods DRE adults with uncontrolled...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Epilepsia Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/epi4.70021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223383264886784 |
|---|---|
| author | Sylvain Rheims Bernhard J. Steinhoff Edouard Hirsch Felix Rosenow Arnaud Biraben Rhys Thomas Alessandro Lovera Paola Lipone Alessandro Comandini Caroline Benoist Elena Alvarez Baron John Paul Leach Karthinathan Thangavelu Agnese Cattaneo |
| author_facet | Sylvain Rheims Bernhard J. Steinhoff Edouard Hirsch Felix Rosenow Arnaud Biraben Rhys Thomas Alessandro Lovera Paola Lipone Alessandro Comandini Caroline Benoist Elena Alvarez Baron John Paul Leach Karthinathan Thangavelu Agnese Cattaneo |
| author_sort | Sylvain Rheims |
| collection | DOAJ |
| description | Abstract Objective Investigate real‐world outcomes in drug‐resistant epilepsy (DRE) patients treated with cenobamate as adjunctive treatment to other antiseizure medications (ASMs) within the Early Access Programs (EAP) in Germany, France, and the United Kingdom. Methods DRE adults with uncontrolled focal‐onset seizures were included from 19 hospitals participating in the EAP in this retrospective study. Data were sourced from clinical records. Participants were evaluated at baseline, 1 months, and 3 months from cenobamate start, and 3, 6, and 12 months after maintenance. The primary effectiveness endpoint was the 50% responder rate, defined as the reduction in seizure frequency ≥50%. Results Data were collected from 298 patients who received at least one dose of cenobamate; efficacy was evaluated on 216 patients with seizure data available. At baseline, the median epilepsy duration was 22.2 years, and 41.9% of patients had previous epilepsy surgery, including vagus nerve stimulation, with a median of nine previously failed ASMs. The median number of seizures/month was 8.8. After 3 months of maintenance, the 50% responder rate (primary endpoint) was 49.3%; the median percentage seizure reduction from baseline was 49.1%. A total of 100%, ≥90%, and ≥75% seizures reduction were reported in 13.6%, 20.0%, and 33.6% of patients, respectively. Both the responder rate and the median percentage seizure reduction steadily increased during the observation period. At 6‐month maintenance, the seizure‐free rate was 24.2%. The retention rate assessed by Kaplan–Meier decreased from 96.6% at 1‐month cenobamate start to 69.7% at 12‐month maintenance. Adverse Drug Reactions (ADRs) to cenobamate occurred in 30.9% of patients, with asthenia, dizziness, and somnolence being the most frequent; the majority were mild‐to‐moderate and resolved during the observation period; three patients (1.0%) experienced a total of seven serious ADRs, all during titration. Significance In this study, cenobamate demonstrated to be an effective option for people with uncontrolled epilepsy even after multiple failed ASMs or failure of epilepsy surgery. Plain Language Summary This study involved patients with drug‐resistant epilepsy, who had continued seizures despite using at least two antiseizure medications (ASMs). Patients received cenobamate (Ontozry) as epilepsy treatment during the Early Access Program (EAP) in France, Germany, and the United Kingdom. An EAP allows patients to receive promising new drugs under clinical supervision before they are commercially available. After 6 months from cenobamate start, 49.3% of patients had their seizures cut by half or more, and 13.6% became seizure‐free. A total of 30.9% of patients had an undesirable reaction to cenobamate, mostly mild‐to‐moderate and resolved; the most frequent were asthenia, dizziness, and somnolence. |
| format | Article |
| id | doaj-art-8d3fa6f260094fd78c5077e2b4048d4a |
| institution | OA Journals |
| issn | 2470-9239 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Epilepsia Open |
| spelling | doaj-art-8d3fa6f260094fd78c5077e2b4048d4a2025-08-20T02:05:59ZengWileyEpilepsia Open2470-92392025-06-0110373674810.1002/epi4.70021Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United KingdomSylvain Rheims0Bernhard J. Steinhoff1Edouard Hirsch2Felix Rosenow3Arnaud Biraben4Rhys Thomas5Alessandro Lovera6Paola Lipone7Alessandro Comandini8Caroline Benoist9Elena Alvarez Baron10John Paul Leach11Karthinathan Thangavelu12Agnese Cattaneo13Department of Functional Neurology and Epileptology Hospices Civils de Lyon and Lyon 1 University Lyon FranceDepartment for Adults Kork Epilepsy Center Kehl‐Kork GermanyFrancis Rohmer Neurology Epilepsy Units, National Institute of Health and Medical Research 1258, Federation of Translational Medicine of Strasbourg Strasbourg University Strasbourg FranceEpilepsy Center Frankfurt Rhine‐Main, Center of Neurology and Neurosurgery, University Hospital Frankfurt Goethe University Frankfurt Frankfurt am Main GermanyEpilepsy Unit, Neurology Department CHU Pontchaillou Rennes FranceDepartment of Neurology Royal Victoria Infirmary Newcastle Upon Tyne UKGlobal Medical Department Angelini Pharma S.p.A Rome ItalyGlobal Medical Department Angelini Pharma S.p.A Rome ItalyGlobal Medical Department Angelini Pharma S.p.A Rome ItalyGlobal Medical Department Angelini Pharma S.p.A Rome ItalyGlobal Medical Department Angelini Pharma S.p.A Rome ItalyGlobal Medical Department Angelini Pharma S.p.A Rome ItalyStatistics Department Medastats, LLC Tampa Florida USAGlobal Medical Department Angelini Pharma S.p.A Rome ItalyAbstract Objective Investigate real‐world outcomes in drug‐resistant epilepsy (DRE) patients treated with cenobamate as adjunctive treatment to other antiseizure medications (ASMs) within the Early Access Programs (EAP) in Germany, France, and the United Kingdom. Methods DRE adults with uncontrolled focal‐onset seizures were included from 19 hospitals participating in the EAP in this retrospective study. Data were sourced from clinical records. Participants were evaluated at baseline, 1 months, and 3 months from cenobamate start, and 3, 6, and 12 months after maintenance. The primary effectiveness endpoint was the 50% responder rate, defined as the reduction in seizure frequency ≥50%. Results Data were collected from 298 patients who received at least one dose of cenobamate; efficacy was evaluated on 216 patients with seizure data available. At baseline, the median epilepsy duration was 22.2 years, and 41.9% of patients had previous epilepsy surgery, including vagus nerve stimulation, with a median of nine previously failed ASMs. The median number of seizures/month was 8.8. After 3 months of maintenance, the 50% responder rate (primary endpoint) was 49.3%; the median percentage seizure reduction from baseline was 49.1%. A total of 100%, ≥90%, and ≥75% seizures reduction were reported in 13.6%, 20.0%, and 33.6% of patients, respectively. Both the responder rate and the median percentage seizure reduction steadily increased during the observation period. At 6‐month maintenance, the seizure‐free rate was 24.2%. The retention rate assessed by Kaplan–Meier decreased from 96.6% at 1‐month cenobamate start to 69.7% at 12‐month maintenance. Adverse Drug Reactions (ADRs) to cenobamate occurred in 30.9% of patients, with asthenia, dizziness, and somnolence being the most frequent; the majority were mild‐to‐moderate and resolved during the observation period; three patients (1.0%) experienced a total of seven serious ADRs, all during titration. Significance In this study, cenobamate demonstrated to be an effective option for people with uncontrolled epilepsy even after multiple failed ASMs or failure of epilepsy surgery. Plain Language Summary This study involved patients with drug‐resistant epilepsy, who had continued seizures despite using at least two antiseizure medications (ASMs). Patients received cenobamate (Ontozry) as epilepsy treatment during the Early Access Program (EAP) in France, Germany, and the United Kingdom. An EAP allows patients to receive promising new drugs under clinical supervision before they are commercially available. After 6 months from cenobamate start, 49.3% of patients had their seizures cut by half or more, and 13.6% became seizure‐free. A total of 30.9% of patients had an undesirable reaction to cenobamate, mostly mild‐to‐moderate and resolved; the most frequent were asthenia, dizziness, and somnolence.https://doi.org/10.1002/epi4.70021antiseizure medicationcenobamateresponder rateseizure freedom |
| spellingShingle | Sylvain Rheims Bernhard J. Steinhoff Edouard Hirsch Felix Rosenow Arnaud Biraben Rhys Thomas Alessandro Lovera Paola Lipone Alessandro Comandini Caroline Benoist Elena Alvarez Baron John Paul Leach Karthinathan Thangavelu Agnese Cattaneo Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom Epilepsia Open antiseizure medication cenobamate responder rate seizure freedom |
| title | Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom |
| title_full | Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom |
| title_fullStr | Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom |
| title_full_unstemmed | Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom |
| title_short | Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom |
| title_sort | real world effectiveness and tolerability of cenobamate in drug resistant epilepsy a retrospective analysis of the patients included into the early access programs eap in germany france and united kingdom |
| topic | antiseizure medication cenobamate responder rate seizure freedom |
| url | https://doi.org/10.1002/epi4.70021 |
| work_keys_str_mv | AT sylvainrheims realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT bernhardjsteinhoff realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT edouardhirsch realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT felixrosenow realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT arnaudbiraben realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT rhysthomas realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT alessandrolovera realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT paolalipone realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT alessandrocomandini realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT carolinebenoist realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT elenaalvarezbaron realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT johnpaulleach realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT karthinathanthangavelu realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom AT agnesecattaneo realworldeffectivenessandtolerabilityofcenobamateindrugresistantepilepsyaretrospectiveanalysisofthepatientsincludedintotheearlyaccessprogramseapingermanyfranceandunitedkingdom |